Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
How are you integrating Prostox into your practice for prostate patients deciding between SBRT and hypofractionation?
Related Questions
Does long term use of 5 alpha reductase inhibitors change the way you evaluate a PSMA PET?
How would you treat a patient with isolated CNS relapse of seminoma?
How do you manage PSA progression while a patient is on Xofigo or Pluvicto?
How do you interpret nodes with minimal increased uptake on PSMA PET in prostate cancer?
How would you optimally boost patients with high or very high risk prostate cancer receiving definitive radiotherapy in 2025?
In platinum-refractory or multiply-relapsed NSGCT with 1–2 progressive sites and no good surgical option, is there a role for local radiotherapy (e.g., SBRT) to those sites?
Would you offer re-irradiation for a prostate local recurrence after I-125 seed implant >10 years ago in a healthy young patient with life expectancy >15 years?
How would you treat an isolated urothelial cancer local recurrence abutting the duodenum?
How often do you utilize intrafraction motion tracking when treating prostate cancer?
What are your institution's standard liquid intake instructions for prostate cancer patients going through definitive external beam radiation?
